Global Sickle Cell Disease Treatment Market Future Outlook and by Top key players Analysis Addmedica, Emmaus Medical, Inc., Global Blood Therapeutics Inc., bluebird bio, Inc.
Global Sickle Cell Disease Treatment Market report involves the drivers and restraints for the Global Sickle Cell Disease Treatment Market that are derived from SWOT analysis, and also shows what all the recent developments, product launches, joint ventures, mergers and acquisitions by the several key players and brands that are driving the market are by systemic company profiles. It also includes production, revenue, and average product price and market shares of key players. This study will help market participants to get a good understanding of future development of the market and industry. Highlights about the key business priorities assist the companies to realign their business strategies.
Market Analysis:
Global sickle cell disease treatment market is rising gradually with a healthy CAGR of 11.5% in the forecast period of 2019-2026. The report contains data of the base year 2018 and historic year 2017. Increasing incidence of sickle cell disease in different regions and high demand of unmet medical needs are driving the global sickle cell disease treatment market.
Get Sample Report + All Related Graphs & Charts @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-sickle-cell-disease-treatment-market
Key Market Players:
Few of the major competitors currently working in global sickle cell disease treatment market are Addmedica, Emmaus Medical, Inc., Global Blood Therapeutics Inc., bluebird bio, Inc., Pfizer Inc., Novartis AG, Bristol-Myers Squibb Company, Endo Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Mayne Pharma Group Limited, CELGENE CORPORATION, Ironwood Pharmaceuticals, Inc., Amgen Inc., Zydus Cadila, Silver Lake Research Corporation, Ionis Pharmaceuticals, Inc., Vertex Pharmaceuticals Incorporated, Alkem Labs, Purdue Pharma L.P among others.
Competitive Analysis:
Global sickle cell disease treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of sickle cell disease treatment market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Global Sickle Cell Disease Treatment Market By Type (Hemoglobin Sβ0 Thalassemia, Hemoglobin Sβ+ Thalassemia, Hemoglobin SC, Others), Symptoms Type (Anemia, Episodes of Pain, Frequent Infections, Others), Complications Type (Stroke, Acute Chest Syndrome, Pulmonary Hypertension, Organ Damage, Others), Treatments Type (Medication, Blood Transfusion, Bone Marrow Transplantation, Others), Medications Type (Antibiotics, Pain-Relieving Medications, Hydroxyurea, Others), Route of Administration (Oral, Injectable, Others), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Industry Trends and Forecast to 2026
Market Definition: Global Sickle Cell Disease Treatment Market
Sickle cell disease (SCD) is the most common hereditary blood disorders. In this condition, red blood cells fail to supply adequate amount of oxygen in body. Normally red blood cells are flexible and round but in SDC obtain irregular shapes such as sickle or crescent moons and get stuck in small blood vessels blocking the way of blood flow.
The presence of SCD in black Americans is approximately 8%. The expected prevalence of sickle cell anemia in the United States is 1 in 625 persons at birth.
Market Drivers
- Increase in immigration of African population can be the major driver for growth of the market
- Improvement in healthcare services and investment in treatment of sickle cell disease propel the market growth
- Rising cases of sickle cell diseases in North America region can boost up the global market growth
- High demand of regenerative therapies and strong pipeline may escalate the market in the forecast period
Market Restraints
- Lack of effective treatment options in Middle-East and Africa plays important role in challenging the market growth
- Unavailability of drugs in rural areas is obstructing the growth of the market
- High cost of treatment and low healthcare expenditure in some countries may hamper the market growth
Grab Your Report at an Impressive 30% Discount! Please click Here@https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-sickle-cell-disease-treatment-market
Segmentation: Global Sickle Cell Disease Treatment Market
By Type
- Hemoglobin Sβ0 Thalassemia
- Hemoglobin Sβ+ Thalassemia
- Hemoglobin SC
- Others
By Symptoms
- Anemia
- Episodes of Pain
- Frequent Infections
- Others
By Complications
- Stroke
- Acute Chest Syndrome
- Pulmonary Hypertension
- Organ Damage
- Others
By Treatment
- Medication
- Blood Transfusion
- Bone Marrow Transplantation
- Others
By Medications
- Antibiotics
- Pain-Relieving Medications
- Hydroxyurea
- Others
By Route of Administration
- Oral
- Injectable
- Others
By End Users
- Hospitals
- Homecare
- Specialty Clinics
- Others
By Distribution Channels
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
- Others
By Geography
- North America
- South America
- Europe
- Asia-Pacific
- Middle East & Africa
Key Developments in the Market:
- In July 2019, Novartis AG received the Biologics License Application (BLA) for crizanlizumab (SEG101), an investigational sickle cell medicine used for preventing vaso-occlusive crises (VOCs) in patients with sickle cell disease. This BLA grant to the drug candidate of Novartis AG will provide the marketing authorizations of the drug in interstate market and supports the development of the product for commercialization internationally
- In December 2017, Addmedica received the U.S. FDA approval for Siklos (hydroxyurea), a drug that reduces the frequency of painful crises and blood transfucion requirements in pediatric patients suffering from sicle cell anemia. The approval is a major development for treatment of children with sickle cell anemia
Reasons to Purchase this Report
- Current and future of global sickle cell disease treatment market outlook in the developed and emerging markets
- The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
- Regions/Countries that are expected to witness the fastest growth rates during the forecast period
- The latest developments, market shares, and strategies that are employed by the major market players
Note: If you have any special requirements, please let us know and we will offer you the report as you want.
About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Contact:
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email: [email protected]
